Biotech Videos
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests
NewsDealsSocialBlogsVideosPodcasts
BiotechVideosOral GLP-1 Breakthrough - Arecor CEO on Improving Bioavailability for Obesity Treatment
Euro StocksBioTechHealthcare

Oral GLP-1 Breakthrough - Arecor CEO on Improving Bioavailability for Obesity Treatment

•February 16, 2026
0
Proactive Investors
Proactive Investors•Feb 16, 2026

Original Description

Arecor Therapeutics PLC is targeting a pivotal 2026. CEO Sarah Howell outlines plans to launch a Phase 2 trial for next-generation insulin AT278 in partnership with Sequel Med Tech, while advancing an oral GLP-1 program aimed at improving bioavailability beyond current market standards.
With cash runway into 2027 and key clinical milestones ahead, Arecor is positioning for a milestone-driven year.
#ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors
0

Comments

Want to join the conversation?

Loading comments...